Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Biotechnology

Oligomerix

James Moe

William Erhardt

Robert Foerster

Jack Pasini

Eliot J. Davidowitz

The Advisory Team at Oligomerix provides strategic guidance and expert insights to advance the company’s mission of developing therapeutics for Alzheimer’s disease. Comprising experienced advisors, the team offers counsel on scientific research, regulatory pathways, and commercialization strategies to ensure the successful progression of Oligomerix's drug discovery pipeline.

Advisory Team

Leadership Team

Scientific and Research Team

Advisory Team

About

Team members

Other teams at Oligomerix

Leadership Team

Scientific and Research Team